Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Alnylam Pharmaceuticals stock | $141.99
Learn how to easily invest in Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals, Inc is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Alnylam Pharmaceuticals employs 1,453 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Alnylam Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ALNY – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Alnylam Pharmaceuticals stock price (NASDAQ: ALNY)Use our graph to track the performance of ALNY stocks over time.
Alnylam Pharmaceuticals shares at a glance
|Latest market close||$141.99|
|52-week range||$119.29 - $184.45|
|50-day moving average||$173.47|
|200-day moving average||$152.81|
|Wall St. target price||$174.78|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-8.25|
Buy Alnylam Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Alnylam Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Alnylam Pharmaceuticals price performance over time
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||-17.17%|
|3 months (2021-05-04)||7.92%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
Alnylam Pharmaceuticals financials
|Revenue TTM||$570.9 million|
|Gross profit TTM||$414.8 million|
|Return on assets TTM||-18.17%|
|Return on equity TTM||-77.01%|
|Market capitalisation||$21.4 billion|
TTM: trailing 12 months
Shorting Alnylam Pharmaceuticals shares
There are currently 4.2 million Alnylam Pharmaceuticals shares held short by investors – that's known as Alnylam Pharmaceuticals's "short interest". This figure is 2.4% down from 4.3 million last month.
There are a few different ways that this level of interest in shorting Alnylam Pharmaceuticals shares can be evaluated.
Alnylam Pharmaceuticals's "short interest ratio" (SIR)
Alnylam Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Alnylam Pharmaceuticals shares currently shorted divided by the average quantity of Alnylam Pharmaceuticals shares traded daily (recently around 757982.58527828). Alnylam Pharmaceuticals's SIR currently stands at 5.57. In other words for every 100,000 Alnylam Pharmaceuticals shares traded daily on the market, roughly 5570 shares are currently held short.
However Alnylam Pharmaceuticals's short interest can also be evaluated against the total number of Alnylam Pharmaceuticals shares, or, against the total number of tradable Alnylam Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alnylam Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Alnylam Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0361% of the tradable shares (for every 100,000 tradable Alnylam Pharmaceuticals shares, roughly 36 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Alnylam Pharmaceuticals.
Find out more about how you can short Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals share dividends
We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.
Alnylam Pharmaceuticals share price volatility
Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $119.29 up to $184.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 1.228. This would suggest that Alnylam Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Alnylam Pharmaceuticals overview
Alnylam Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc.
Stocks similar to Alnylam Pharmaceuticals
Alnylam Pharmaceuticals in the news
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q2 2021 Results - Earnings Call Transcript
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
Frequently asked questionsWhat percentage of Alnylam Pharmaceuticals is owned by insiders or institutions?
Currently 0.615% of Alnylam Pharmaceuticals shares are held by insiders and 94.788% by institutions. How many people work for Alnylam Pharmaceuticals?
Latest data suggests 1,453 work at Alnylam Pharmaceuticals. When does the fiscal year end for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's fiscal year ends in December. Where is Alnylam Pharmaceuticals based?
Alnylam Pharmaceuticals's address is: 675 West Kendall Street, Cambridge, MA, United States, 02142 What is Alnylam Pharmaceuticals's ISIN number?
Alnylam Pharmaceuticals's international securities identification number is: US02043Q1076 What is Alnylam Pharmaceuticals's CUSIP number?
Alnylam Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 02043Q107
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert